Quick-Med’s patented technology, Nimbus is a antimicrobial technology that has been custom designed for wound care and other medical applications. Nimbus received de Novo FDA clearance in 2009
Caraco Pharma earned net income of $1.2m during the first quarter of Fiscal 2011, as compared to incurring a net loss of $9.4m during the corresponding period of
Anturol gel Phase 3 trial conducted under a special protocol assessment (SPA) with FDA, was a double blind, randomised, parallel placebo-controlled multi-center study which evaluated the efficacy and
Prior to joining Caraco Pharmaceutical Laboratories, Mr Singh worked as senior vice president of business strategies at Caraco Pharmaceutical Laboratories from July 2007 to July 2010. Previously, Mr
PPD has posted a net income of $21m for the second quarter of 2010 or $0.18 per diluted share, compared to $58.1m or $0.49 per diluted share, for
Dr Martin brings with him 20 years of experience in the biotechnology industry. Before joining Dynavax Technologies, Dr Martin served as a president of Humabs. Prior to that
Upp Technology’s software selected from the suite includes IRMS|EM Emergency Management, IRMS|WM Warehouse Management and IRMS|BI Business Intelligence to provide the BSPS with real-time visibility, enhanced accuracy and
The kit combines Gentel’s APiX chromogenic detection platform and Clontech’s research-validated Antibody 380 array technology to help scientists study tumor-associated antigens, compare proteomic and transcriptomic data, and perform
MorphoSys has posted a net profit of EUR2.7m for the second quarter 2010 compared to net profit of EUR1.5m for the comparable period in 2009. Operating profit was
Genzyme said as per the final rule, these medications, including its Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014. Renvela is indicated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.